In fact, combinations of these modulators are being offered to F508del CF patients to target both structural and functional CFTR defects; however, their effect on fundamental macrophage functions is still unclear (Heijerman et al., 2019; Rogers et al., 2019; Ridley and Condren, 2020). This evidence concerns the gene CFTR and cystic fibrosis.